Abstract
Target-directed drug design, although a conceptually rational approach, is only one strategy for drug discovery. In the case of neurodegenerative diseases where molecular targets and disease mechanisms are unknown, even when specific genes are known to trigger the disease, phenotypic screening offers another approach. This review describes the establishment of phenotypic screening assays using primary neurons subjected to a disease-relevant pathophysiological stress and measuring the most important functional outcome, survival. Although a challenge both to screening teams to reproducibly produce the cells and chemists to interpret structure-activity relationships, such systems have historically identified or produced effective drugs. The primary screening assay is only the start; once hits are validated, they must be characterized using traditional target-directed or mechanism-based secondary assays to establish their selectivity, lack of side-effect liability, and eventually be shown to produce the desired effects in a preclinical animal model of the disease. These compounds then provide valuable pharmacological tools to identify neurodegenerative disease targets and mechanisms, whether or not they have all the properties required of a drug candidate.
Keywords: Motor neuron disease, Huntington's disease, cell-based assays, drug discovery, chemical genetics, phenotypic screening, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, riluzole, PREDICT-HD, Dyslipidemia, Analgesia, Diabetes, epilepsy, Eflornithine, Rogain, Viagra, phenotypic screening assays, olesoxime, TRO19622, spinal muscular atrophy, chemotherapy-induced neuropathy, electroporation, BDNF, mPTP, mitochondrial dysfunction, black-box, C. elegans, drosophila
CNS & Neurological Disorders - Drug Targets
Title: Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
Volume: 9 Issue: 6
Author(s): R. M. Pruss
Affiliation:
Keywords: Motor neuron disease, Huntington's disease, cell-based assays, drug discovery, chemical genetics, phenotypic screening, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, riluzole, PREDICT-HD, Dyslipidemia, Analgesia, Diabetes, epilepsy, Eflornithine, Rogain, Viagra, phenotypic screening assays, olesoxime, TRO19622, spinal muscular atrophy, chemotherapy-induced neuropathy, electroporation, BDNF, mPTP, mitochondrial dysfunction, black-box, C. elegans, drosophila
Abstract: Target-directed drug design, although a conceptually rational approach, is only one strategy for drug discovery. In the case of neurodegenerative diseases where molecular targets and disease mechanisms are unknown, even when specific genes are known to trigger the disease, phenotypic screening offers another approach. This review describes the establishment of phenotypic screening assays using primary neurons subjected to a disease-relevant pathophysiological stress and measuring the most important functional outcome, survival. Although a challenge both to screening teams to reproducibly produce the cells and chemists to interpret structure-activity relationships, such systems have historically identified or produced effective drugs. The primary screening assay is only the start; once hits are validated, they must be characterized using traditional target-directed or mechanism-based secondary assays to establish their selectivity, lack of side-effect liability, and eventually be shown to produce the desired effects in a preclinical animal model of the disease. These compounds then provide valuable pharmacological tools to identify neurodegenerative disease targets and mechanisms, whether or not they have all the properties required of a drug candidate.
Export Options
About this article
Cite this article as:
M. Pruss R., Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237377
DOI https://dx.doi.org/10.2174/187152710793237377 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Proteins Structures in Leishmania Amastigotes for Clinical Remission of Psoriasis
Current Proteomics HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages
Current Topics in Medicinal Chemistry Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Clinical Pharmacokinetics of Retigabine/Ezogabine
Current Clinical Pharmacology Optimized Feature Selection for Enhanced Epileptic Seizure Detection
Current Medical Imaging Status Analysis of Herbal Drug Therapies in Epilepsy: Advancements in the Use of Medicinal Plants with Anti-inflammatory Properties
Combinatorial Chemistry & High Throughput Screening Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews New Highlights in the Regulation of Cells Proliferation
Neuroscience and Biomedical Engineering (Discontinued) Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery